Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Merck Announces The Acquisition Of TGFβ Focused Tilos Therapeutics

By John F. Heerdink, Jr.
Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the leading edge of research. This week Merck announced that it is acquiring a privately owned biopharmaceutical company, Tilos Therapeutics. Founded by Boehringer Ingelheim Venture Fund and Partners Innovation Fund, Tilos mainly focusses on TGFβ a potent cytokine that plays an important role in the treatment of cancer and fibrotic diseases.
Dr. Dean Li, senior VP, discovery and translational medicine, Merck stated, “Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGFβ by binding to latency-associated peptide, with potential applications across a range of disease indications.”
It was reported that Merck will be buying all outstanding shares of Tilos through a subsidiary for approximately $773 million in an upfront payment including contingent milestone payments, as per the terms of the agreement.
Dr. Barbara Fox, CEO, Tilos stated “This agreement with Merck, an industry leader in biopharmaceutical research and development, provide meaningful validation for our therapeutic approach and best positions our pipeline for broad clinical and commercial success.” as reported.
To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page. If you found this story interesting you should consider reading about Seattle-based Atossa Genetics (Nasdaq: ATOS) which is is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. To learn more please see the Atossa dedicated coverage page at Vista Partners.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. Stay Informed! Stay Competitive! Join us at Vista Partners! It’s FREE to receive email updates. 6

Merck to Acquire Tilos Therapeutics

Merck (MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis..
Read Full Article


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us